We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.85B
AUM Growth
+$217M
Cap. Flow
+$578M
Cap. Flow %
8.44%
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$112M
2
APLS
Apellis Pharmaceuticals
APLS
+$78.4M
3
PEN icon
Penumbra
PEN
+$62.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$54.4M
5
ARGX icon
argenx
ARGX
+$53.9M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$153M
2
INMD icon
InMode
INMD
+$19.9M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$17.3M
4
AGEN
Agenus
AGEN
+$12.9M
5
GH icon
Guardant Health
GH
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.33%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
26
Protagonist Therapeutics
PTGX
$9.49B
$88.9M 1.3%
2,599,822
+846,127
+48% +$26.7M
STOK icon
27
Stoke Therapeutics
STOK
$2.11B
$87.4M 1.28%
3,644,248
– –
GH icon
28
Guardant Health
GH
$22.7B
$81.3M 1.19%
813,342
-112,000
-12% -$11.6M
CCCC icon
29
C4 Therapeutics
CCCC
$408M
$80.3M 1.17%
2,494,965
– –
PMVP icon
30
PMV Pharmaceuticals
PMVP
$64M
$68.9M 1.01%
2,980,960
+2,171,097
+268% +$52.5M
FULC icon
31
Fulcrum Therapeutics
FULC
$296M
$68.4M 1%
3,866,872
+11,581
+0.3% +$229K
MGNX icon
32
MacroGenics
MGNX
$255M
$63.8M 0.93%
3,975,554
– –
AXSM icon
33
Axsome Therapeutics
AXSM
$11B
$61.2M 0.89%
1,618,819
+2,322
+0.1% +$85.4K
RGNX icon
34
Regenxbio
RGNX
$710M
$60.3M 0.88%
1,845,366
– –
IDYA icon
35
IDEAYA Biosciences
IDYA
$3.55B
$59.6M 0.87%
2,520,076
-746,179
-23% -$17.3M
CUTR
36
DELISTED
Cutera, Inc.
CUTR
$57.7M 0.84%
1,397,063
+139,201
+11% +$5.71M
PRQR icon
37
ProQR Therapeutics
PRQR
$267M
$56.3M 0.82%
7,027,725
+584,612
+9% +$4.45M
BCYC
38
Bicycle Therapeutics
BCYC
$293M
$52.9M 0.77%
+869,271
New +$48M
ACET icon
39
Adicet Bio
ACET
$75.5M
$52.9M 0.77%
+188,984
New +$32.4M
SRPT icon
40
Sarepta Therapeutics
SRPT
$1.77B
$52.4M 0.77%
+582,265
New +$49.8M
GHRS icon
41
GH Research
GHRS
$2.06B
$50.6M 0.74%
2,168,957
– –
SNCE
42
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$49.6M 0.72%
198,750
+150,000
+308% +$33.3M
DMTK
43
DELISTED
DermTech, Inc. Common Stock
DMTK
$49.3M 0.72%
3,118,666
+1
+0% +$24
RLMD icon
44
Relmada Therapeutics
RLMD
$522M
$49.3M 0.72%
2,186,324
+648,298
+42% +$14.4M
BLU
45
DELISTED
BELLUS Health Inc.
BLU
$48M 0.7%
5,968,017
+1,000,000
+20% +$6.64M
TNYA icon
46
Tenaya Therapeutics
TNYA
$166M
$46.6M 0.68%
2,458,750
– –
AVDL
47
DELISTED
Avadel Pharmaceuticals
AVDL
$46.4M 0.68%
5,741,939
– –
TARS icon
48
Tarsus Pharmaceuticals
TARS
$2.84B
$45.3M 0.66%
2,013,601
– –
APYX icon
49
Apyx Medical
APYX
$170M
$43.6M 0.64%
3,398,279
– –
IMCR icon
50
Immunocore
IMCR
$1.72B
$42.6M 0.62%
1,245,532
– –
1
2
3 4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q4 2021 Portfolio in Review

As of Q4 2021, RTW Investments held 136 positions worth $6.85B, up 3.3% from $6.63B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

RTW Investments deployed $578M of net new capital in Q4 2021, opening 16 new positions and adding to 27 existing holdings. Its largest new stake was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $17.3M trimmed.

  • RTW Investments's largest Q4 2021 buy was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.
  • RTW Investments added most to Penumbra in Q4 2021, an estimated $62.3M increase.
  • RTW Investments's biggest Q4 2021 reduction was IDEAYA Biosciences, cutting an estimated $17.3M.
  • RTW Investments fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $153M.
  • RTW Investments's ten largest holdings make up 38% of its $6.85B portfolio in Q4 2021.
  • RTW Investments opened 16 new positions and closed 11 in Q4 2021.
  • RTW Investments's portfolio value rose 3.3% quarter-over-quarter to $6.85B.

Based on RTW Investments's 13F filing for Q4 2021, filed 14 Feb 2022.